Sudo Biosciences Raises $116M Series B Financing To Advance Potential Best-In-Class Tyk2 Therapeutics Programs Into The Clinic
PRIVATEDec 20, 2023
Amount Raised
$116 Million
Round Type
Series B
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research
Investors
TPG Angelo GordonVelosity CapitalFrazier Life SciencesEventide Asset ManagementMonograph CapitalSurveyor CapitalSanofi VenturesThe Rise FundTPG Life Sciences InnovationsTpgEnavate Sciences
Description
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital. The Company has raised a total of $157 million funding since its founding in 2020.
Who to call at Sudo Biosciences, and when
A new round usually means Sudo Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Sudo Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Sudo Biosciences, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Sudo Biosciences
Location
Carmel, Indiana, United States
About
Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carmel, IN and London, U.K., Sudo is advancing novel medicines designed to improve patient lives.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sudo Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research